Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells

References

• Avallone A, Delrio P, Guida C, Tatangelo F, Petrillo A, Marone P, Cascini L G, Morrica B, Lastoria S, Parisi V, Budillon A, Comella P. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: A phase I-II study. British Journal of Cancer 2006; 94: 1809–1815
   PubMed Web of Science ®Google Scholar
• Belani C P. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Seminars in Oncology 2004; 31: 25–33
   PubMedGoogle Scholar
• Borch R F. The platinum anti-tumour drugs. Metabolism and action of anti-cancer drugs, G Powis, R A Prough. Taylor & Francis, London 1987; 163–193
   Google Scholar
• Caney C, Singh G, Lukka H, Rainbow A J. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. International Journal of Radiation Biology 2004; 80: 291–299
   PubMed Web of Science ®Google Scholar
• Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi D T. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. International Journal of Radiation Oncology Biology Physics 2002; 52: 1092–1098
   PubMedGoogle Scholar
• Dewit L. Combined treatment of radiation and cis-diamminedichloroplatinum (II): A review of experimental and clinical data. International Journal of Radiation Oncology Biology Physics 1987; 13: 403–426
   PubMed Web of Science ®Google Scholar
• Espinosa M, Martinez M, Aguilar J L, Mota A, De la Garza J G, Maldonado V, Melendez-Zajgla J. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemotherapy and Pharmacology 2005; 55: 301–305
   PubMed Web of Science ®Google Scholar
• Galanski M, Jakupec M A, Keppler B K. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Current Medical Chemistry 2005; 12: 2075–2094
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Maughan T S, Falk S J, McDonald A C. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology (ESMO) 2006; 17: 50–56
   PubMedGoogle Scholar
• Green J A, Kirwan J M, Tierney J F, Symonds P, Fresco L, Collingwood M, Williams C J. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. The Lancet 2001; 358: 781–786
   PubMed Web of Science ®Google Scholar
• Greene M H. Is cisplatin a human carcinogen. Journal of the National Cancer Institut 1992; 84: 306–312
   PubMedGoogle Scholar
• Groen H J, Sleijfer S, Meijer C, Kampinga H H, Konings A W, De Vries E G, Mulder N H. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. British Journal of Cancer 1995; 72: 1406–1411
   PubMedGoogle Scholar
• Haller D G. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology 2004; 31: 10–16
   PubMedGoogle Scholar
• Kartalou M, Essigmann J M. Mechanisms of resistance to cisplatin. Mutation Research 2001; 478: 23–43
   PubMed Web of Science ®Google Scholar
• Khushalani N I, Leichman C G, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. Journal of Clinical Oncology 2002; 20: 2844–2850
   PubMed Web of Science ®Google Scholar
• Kjellstrom J, Kjellen E, Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncologica 2005; 44: 687–693
   PubMed Web of Science ®Google Scholar
• Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Chemoradiation of cervical cancer cells: Targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Research 2002; 62: 7364–7371
   PubMed Web of Science ®Google Scholar
• Leblanc J M, Raaphorst P. Evaluation of cisplatin treatment given concurrently with pulsed irradiation in cisplatin sensitive and resistant human ovarian carcinoma cell lines. International Journal of Radiation Biology 2005; 81: 429–435
   PubMed Web of Science ®Google Scholar
• Muggia F M. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Seminars in Oncology 2004; 31: 17–24
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Mitsuhashi N, Takahashi T, Sakurai H, Niibe H. An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. International Journal of Radiation Biology 1996; 70: 747–753
   PubMed Web of Science ®Google Scholar
• Nehme A, Baskaran R, Nebel S, Fink D, Howell S B, Wang J Y, Christen R D. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. British Journal of Cancer 1999; 79: 1104–1110
   PubMed Web of Science ®Google Scholar
• Ryan D P, Niedzwiecki D, Hollis D, Mediema B E, Wadler S, Tepper J E, Goldberg R M, Mayer R J. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. Journal of Clinical Oncology 2006; 24: 2557–2562
   PubMed Web of Science ®Google Scholar
• Sanderson B JS, Ferguson L R, Denny W A. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutation Research - Fundamental Molecular Mechanisms of Mutation 1996; 355: 59–70
   PubMed Web of Science ®Google Scholar
• Schmidt W, Chaney S G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Research 1993; 53: 799–805
   PubMed Web of Science ®Google Scholar
• Steel G G. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology Physics 1979; 5: 1145–1150
   PubMed Web of Science ®Google Scholar